MedPath

Cheplapharm Registration GmbH

🇩🇪Germany
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

66

CIMA_AEMPS:22
NMPA:18
CANADA:11
+1 more agencies

Drug Approvals

Olanzapine Tablets

Product Name
再普乐
Approval Number
国药准字HJ20160495
Approval Date
Mar 21, 2025
NMPA

Olanzapine Tablets

Product Name
再普乐
Approval Number
国药准字HJ20160497
Approval Date
Mar 21, 2025
NMPA

Olanzapine Tablets

Product Name
再普乐
Approval Number
国药准字HJ20160496
Approval Date
Mar 21, 2025
NMPA

Olanzapine Tablets

Product Name
再普乐
Approval Number
国药准字HJ20160494
Approval Date
Mar 21, 2025
NMPA

Olanzapine Orally Disintegrating Tablets

Product Name
奥氮平口崩片
Approval Number
国药准字HJ20160532
Approval Date
Feb 23, 2024
NMPA

Olanzapine Orally Disintegrating Tablets

Product Name
奥氮平口崩片
Approval Number
国药准字HJ20160535
Approval Date
Feb 23, 2024
NMPA

Olanzapine Orally Disintegrating Tablets

Product Name
奥氮平口崩片
Approval Number
国药准字HJ20160534
Approval Date
Feb 23, 2024
NMPA

Olanzapine Orally Disintegrating Tablets

Product Name
奥氮平口崩片
Approval Number
国药准字HJ20160530
Approval Date
Feb 23, 2024
NMPA

Olanzapine Orally Disintegrating Tablets

Product Name
奥氮平口崩片
Approval Number
国药准字HJ20160529
Approval Date
Feb 23, 2024
NMPA

Olanzapine Orally Disintegrating Tablets

Product Name
奥氮平口崩片
Approval Number
国药准字HJ20160536
Approval Date
Feb 23, 2024
NMPA
  • Prev
  • 1
  • 2
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.